TG Therapeutics Inc. (TGTX)

7.97
0.17 2.18
NASDAQ : Health Technology
Prev Close 7.80
Open 7.80
Day Low/High 7.67 / 7.99
52 Wk Low/High 3.32 / 12.90
Volume 977.53K
Avg Volume 1.52M
Exchange NASDAQ
Shares Outstanding 90.83M
Market Cap 715.78M
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)
Insider Trading Alert - BLOX, ILMN And TGTX Traded By Insiders

Insider Trading Alert - BLOX, ILMN And TGTX Traded By Insiders

Stocks with insider trader activity include BLOX, ILMN and TGTX

TG Therapeutics, Inc. Announces Issuance Of Composition Of Matter Patent For TG-1101 In The United States

TG Therapeutics, Inc. Announces Issuance Of Composition Of Matter Patent For TG-1101 In The United States

Patent protection for TG-1101 in the US through mid-2029

7 Stocks Under $10 to Trade for Breakout Gains

7 Stocks Under $10 to Trade for Breakout Gains

These stocks trading for less than $10 a share are within range of triggering big breakout trades.

TG Therapeutics, Inc. Announces Pre-Clinical Data Presentation On TGR-1202 At The 2016 American Association For Cancer Research (AACR) Annual Meeting

TG Therapeutics, Inc. Announces Pre-Clinical Data Presentation On TGR-1202 At The 2016 American Association For Cancer Research (AACR) Annual Meeting

Early data begins to elucidate mechanism for differentiated safety profile observed to date for TGR-1202

TG Therapeutics, Inc. To Present At The 28th Annual ROTH Conference

TG Therapeutics, Inc. To Present At The 28th Annual ROTH Conference

Presentation Scheduled for Tuesday March 15, 2016 at 3:30pm PT

TG Therapeutics, Inc. To Host Conference Call On Fourth Quarter And Year-End 2015 Financial Results And Business Update

TG Therapeutics, Inc. To Host Conference Call On Fourth Quarter And Year-End 2015 Financial Results And Business Update

Investor Conference Call to be Held Monday, March 7, 2016 at 4:30pm ET

TG Therapeutics, Inc. Announces Issuance Of Composition Of Matter Patent For TGR-1202 In The United States

TG Therapeutics, Inc. Announces Issuance Of Composition Of Matter Patent For TGR-1202 In The United States

Patent Protection for TGR-1202 in the US Through July of 2033, Exclusive of Patent Term Extensions

TG Therapeutics, Inc. To Present At The 18th Annual BIO CEO & Investor Conference

TG Therapeutics, Inc. To Present At The 18th Annual BIO CEO & Investor Conference

Presentation Scheduled for Monday, February 8, 2016 at 1:00pm

8 Stocks Under $10 Making Big Moves Higher

8 Stocks Under $10 Making Big Moves Higher

There under-$10 stocks are within range of triggering big breakout trades.

TG Therapeutics (TGTX) Highlighted As Weak On High Volume

TG Therapeutics (TGTX) Highlighted As Weak On High Volume

Trade-Ideas LLC identified TG Therapeutics (TGTX) as a weak on high relative volume candidate

First Week of TGTX March 18th Options Trading

First Week of TGTX March 18th Options Trading

Investors in TG Therapeutics Inc saw new options begin trading this week, for the March 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TGTX options chain for the new March 18th contracts and identified one put and one call contract of particular interest.

TG Therapeutics (TGTX) Is Strong On High Volume Today

TG Therapeutics (TGTX) Is Strong On High Volume Today

Trade-Ideas LLC identified TG Therapeutics (TGTX) as a strong on high relative volume candidate

TG Therapeutics, Inc. To Present At The 34th Annual J.P. Morgan Healthcare Conference

TG Therapeutics, Inc. To Present At The 34th Annual J.P. Morgan Healthcare Conference

Presentation Scheduled for Thursday, January 14, 2016 at 9:00am PST

TG Therapeutics is Now Oversold (TGTX)

TG Therapeutics is Now Oversold (TGTX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TG Therapeutics, Inc. Announces Oral Presentation Of Novel Pre-Clinical Combinations With TGR-1202 By Investigators At Columbia University At The 57th American Society Of Hematology Annual Meeting

TG Therapeutics, Inc. Announces Oral Presentation Of Novel Pre-Clinical Combinations With TGR-1202 By Investigators At Columbia University At The 57th American Society Of Hematology Annual Meeting

TGR-1202 Combinations Uniquely Able to Modulate c-Myc Activity, With Significant Potential in the Treatment of Diffuse-Large B-Cell Lymphoma and Other Malignancies

TG Therapeutics, Inc. Recaps Schedule Of Data Presentations At The 57th American Society Of Hematology Annual Meeting

TG Therapeutics, Inc. Recaps Schedule Of Data Presentations At The 57th American Society Of Hematology Annual Meeting

Investor Reception to be Held on Monday December 7, 2015 from 7:45 pm - 9:00 pm ET at the Hyatt Regency Orlando With Presentations by Leading Clinical Investigators

Trade-Ideas: TG Therapeutics (TGTX) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: TG Therapeutics (TGTX) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified TG Therapeutics (TGTX) as a strong on high relative volume candidate

TG Therapeutics, Inc. Announces Third Quarter 2015 Financial Results And Business Update

TG Therapeutics, Inc. Announces Third Quarter 2015 Financial Results And Business Update

Investor Conference Call to be Held Today, Monday, November 9, 2015 at 8:30am ET

TG Therapeutics, Inc. To Host Conference Call On Third Quarter 2015 Financial Results And Business Update

TG Therapeutics, Inc. To Host Conference Call On Third Quarter 2015 Financial Results And Business Update

Investor Conference Call to be Held Monday, November 9, 2015 at 8:30am ET   

Are Drug Stocks What's Ailing the Market?

This move in health care takes your breath away.

Jim Cramer's Top Takeaways: TG Therapeutics, Mallinckrodt, General Electric

Jim Cramer's Top Takeaways: TG Therapeutics, Mallinckrodt, General Electric

Cramer says steer clear of Mallinckrodt and he's a big fan of GE with Nelson Peltz involved.

Jim Cramer's 'Mad Money' Recap: Here's Where the Bear Tide Is Turning

Jim Cramer's 'Mad Money' Recap: Here's Where the Bear Tide Is Turning

When the facts change, investors need to change their minds, Cramer says.

4 Unusual-Volume Stocks to Trade for Breakouts

4 Unusual-Volume Stocks to Trade for Breakouts

These stocks rising on unusual volume are within range of triggering breakout trades.

TheStreet Quant Rating: D- (Sell)